Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
European regulatory authorities have approved Astellas Pharma’s antibody drug conjugate Padcev (enfortumab vedotin) in combination with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for earlier use in bladder cancer. Astellas said on June 24 that the European Commission gave the green light…
To read the full story
Related Article
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Cisplatin-Ineligible Bladder Cancer
May 25, 2026
- EMA Starts Review of Padcev-Keytruda for Perioperative Bladder Cancer
December 2, 2025
BUSINESS
- Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
October 5, 2026
- Taiho, Cullinan Start US Filing for Zipalertinib-Chemo Combo
October 5, 2026
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- AstraZeneca Opens Japan Recruitment for Young Oncologist Program
October 5, 2026
- Cheplapharm to Acquire MA for Kyowa Kirin’s 5-FU Products
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…